416 related articles for article (PubMed ID: 22690078)
1. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
[TBL] [Abstract][Full Text] [Related]
2. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
3. Transferrin dipstick as a potential novel test for colon cancer screening: a comparative study with immuno fecal occult blood test.
Sheng JQ; Li SR; Wu ZT; Xia CH; Wu X; Chen J; Rao J
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2182-5. PubMed ID: 19661074
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.
Hirai HW; Tsoi KK; Chan JY; Wong SH; Ching JY; Wong MC; Wu JC; Chan FK; Sung JJ; Ng SC
Aliment Pharmacol Ther; 2016 Apr; 43(7):755-64. PubMed ID: 26858128
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the immunofecal occult blood test for colorectal cancer screening in a large population.
Yang H; Ge Z; Dai J; Li X; Gao Y
Dig Dis Sci; 2011 Jan; 56(1):203-7. PubMed ID: 20458621
[TBL] [Abstract][Full Text] [Related]
6. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
[TBL] [Abstract][Full Text] [Related]
8. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
9. Combined Plasma MicroRNA and Fecal Occult Blood Tests in Early Detection of Colorectal Cancer.
Luo X; Wu Y; Ji M; Zhang S
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115212
[TBL] [Abstract][Full Text] [Related]
10. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
[TBL] [Abstract][Full Text] [Related]
11. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
Meklin J; SyrjÄnen K; Eskelinen M
Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
[TBL] [Abstract][Full Text] [Related]
12. The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.
Chen CH; Yan SL; Yang TH; Chen SF; Yeh YH; Ou JJ; Lin CH; Lee YT; Chen CH
J Clin Lab Anal; 2017 Jan; 31(1):. PubMed ID: 27390118
[TBL] [Abstract][Full Text] [Related]
13. A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection.
Lohsiriwat V; Thavichaigarn P; Awapittaya B
J Med Assoc Thai; 2007 Nov; 90(11):2291-5. PubMed ID: 18181309
[TBL] [Abstract][Full Text] [Related]
14. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
15. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.
Koga Y; Yamazaki N; Yamamoto Y; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1844-52. PubMed ID: 23950216
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fecal occult blood tests for colorectal cancer screening in an Alaska Native population with high prevalence of Helicobacter pylori infection, 2008-2012.
Redwood D; Provost E; Asay E; Roberts D; Haverkamp D; Perdue D; Bruce MG; Sacco F; Espey D
Prev Chronic Dis; 2014 Apr; 11():E56. PubMed ID: 24721216
[TBL] [Abstract][Full Text] [Related]
17. Colorectal screening using the immunochemical faecal occult blood test kit among the Malaysian cohort participants.
Abdullah N; Abd Jalal N; Ismail N; Kamaruddin MA; Abd Mutalib NS; Alias MR; Mazlan L; Sagap I; Jamal R
Cancer Epidemiol; 2020 Apr; 65():101656. PubMed ID: 31923638
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Fecal Occult Blood Test (FOBT) Colorectal Cancer Screening Using Gut Bacteriome as a Biomarker.
Chowdhury MR; Hone KGMS; Prévost K; Balthazar P; Avino M; Arguin M; Beaudoin J; Malick M; Desgagné M; Robert G; Scott M; Dubé J; Laforest-Lapointe I; Massé E
Clin Colorectal Cancer; 2024 Mar; 23(1):22-34.e2. PubMed ID: 37980216
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of colorectal diseases in immunological fecal occult blood test (I-FOBT) positive patients in a tertiary care hospital in Bangladesh.
Mollick SH; Roy PK; Bhuiyan MR; Mia AR; Alam MS; Mollick KA; Pervin S; Hassan MQ
Mymensingh Med J; 2014 Oct; 23(4):764-9. PubMed ID: 25481598
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
